Hepatic congestion plays a role in liver stiffness
Nora Frulio, Hervé Laumonier, Charles Balabaud, Hervé Trillaud, Paulette Bioulac‐Sage – 29 October 2009
De novo malignancies following liver transplantation: Impact and recommendations
J. Ignacio Herrero – 29 October 2009 – Key Points
Long‐term medical comorbidities and their management: Hypertension/cardiovascular disease
Olaf Guckelberger – 29 October 2009 – Key Points
Health‐related quality of life after liver transplantation for adult recipients
Hillary Bownik, Sammy Saab – 29 October 2009 – Key Points
Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation
Jean‐Charles Duclos‐Vallee, Mylène Sebagh – 29 October 2009 – Key Points
Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A
Sandra Ciesek, Eike Steinmann, Heiner Wedemeyer, Michael P. Manns, Johann Neyts, Norbert Tautz, Vanesa Madan, Ralf Bartenschlager, Thomas von Hahn, Thomas Pietschmann – 29 October 2009 – Numerous anti‐hepatitis C virus (HCV) drugs targeting either the viral nonstructural 3 (NS3) protease or NS5B polymerase are currently in clinical testing. However, rapid resistance development is a major problem and optimal therapy will clearly require a combination of multiple mechanisms of action.
Sirtuins and the hepatic regulation of energy homeostasis
Puneet Puri, Arun J. Sanyal – 29 October 2009
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C
Neal D. Freedman, James E. Everhart, Karen L. Lindsay, Marc G. Ghany, Teresa M. Curto, Mitchell L. Shiffman, William M. Lee, Anna S. Lok, Adrian M. Di Bisceglie, Herbert L. Bonkovsky, John C. Hoefs, Jules L. Dienstag, Chihiro Morishima, Christian C. Abnet, Rashmi Sinha, HALT‐C Trial Group – 29 October 2009 – Higher coffee consumption has been associated inversely with the incidence of chronic liver disease in population studies. We examined the relationship of coffee consumption with liver disease progression in individuals with advanced hepatitis C–related liver disease.
Chronically inflamed livers up‐regulate expression of inhibitory B7 family members
Rachel Kassel, Michael W. Cruise, Julia C. Iezzoni, Nicholas A. Taylor, Timothy L. Pruett, Young S. Hahn – 29 October 2009 – Hepatitis B virus, hepatitis C virus, autoimmune hepatitis, and nonalcoholic fatty liver disease can induce chronic liver disease. The Programmed Death‐1 (PD‐1) inhibitory pathway assists in T cell response regulation during acute and chronic inflammation and participates in the progression of inflammatory liver disease.
The strength of the Fas ligand signal determines whether hepatocytes act as type 1 or type 2 cells in murine livers
Sven Schüngel, Laura Elisa Buitrago‐Molina, Padmavathi devi Nalapareddy, Margitta Lebofsky, Michael P. Manns, Hartmut Jaeschke, Atan Gross, Arndt Vogel – 29 October 2009 – The BH3‐interacting domain death agonist Bid has been shown to be critical for Fas‐induced hepatocellular apoptosis. Furthermore, some studies have suggested that phosphorylation of Bid may determine its apoptotic function and may act as a switch to nonapoptotic functions. The aim of this study was to evaluate the role of Bid and phosphorylated Bid for Fas ligand (FasL)‐induced apoptosis in murine livers.